Welcome to the CJU website » LOG IN


Molecular targeted therapies for renal cell carcinoma
Dec  2007 (Vol.  14, Issue  61, Pages( 48 - 52)
PMID: 18163945


Text-Size + 

  • New advances in technology to directly target specific molecular events in the proliferation of cancer have led to promising results in renal cell carcinoma. Response rates in excess of 70% and complete responses in advanced (metastatic) renal cell carcinoma have caused a change in the paradigm of treatment from immunotherapy. Toxicities are significant, but manageable and pushing the toxicity to tolerability may increase the response rate.